{
    "nctId": "NCT00434356",
    "briefTitle": "A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)",
    "officialTitle": "A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Best Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed Informed Consent Form\n* Histologically or cytologically confirmed adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease\n* Age \u2265 18 years\n* Adequate left ventricular function at study entry, defined as an Left Ventricular Ejection Fraction (LVEF) \\> 50% by either Multi Gated Acquisition(MUGA) scan or Electrocardiogram (ECHO)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Ability and willingness to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n* Unknown HER2 status or known HER2-positive status\n* Prior chemotherapy for locally recurrent or metastatic disease\n* Prior hormonal therapy within 2 weeks prior to Day 1\n* Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to Day 1\n* Prior adjuvant or neoadjuvant non-taxane chemotherapy within 6 months prior to Day 1\n* For patients who have received recent radiotherapy, ongoing Grade \u2265 3 acute toxicity\n* Patients with brain metastasis on full dose anticoagulation therapy\n* Life expectancy of \\< 12 weeks\n* Current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study\n* Inadequate organ function within 28 days prior to Day 1\n* Untreated abnormal thyroid function tests\n* Uncontrolled serious medical or psychiatric illness\n* Active infection requiring IV antibiotics at enrollment or randomization\n* History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix\n* Inadequately controlled hypertension\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association (NYHA) Class II or greater CHF\n* History of myocardial infarction or unstable angina within 12 months prior to Day 1\n* History of stroke or transient ischemic attack within 12 months prior to Day 1\n* Known central nervous system (CNS) disease except for treated brain metastasis\n* Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1\n* History of hemoptysis within 1 month prior to Day 1\n* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study\n* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1\n* History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1\n* Serious, non-healing wound, active ulcer, or untreated bone fracture\n* Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of \u2265 1.0 at screening\n* Known hypersensitivity to any component of bevacizumab or sunitinib\n* Pregnancy (positive pregnancy test) or lactation",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}